Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria

Infections caused by multi-resistant Gram-negative bacteria, particularly Pseudomonas aeruginosa, are increasing worldwide. In patients with cystic fibrosis (CF), resistance in P. aeruginosa to numerous anti-pseudomonal agents is becoming common. The absence since 1995, of new substances active agai...

Full description

Saved in:
Bibliographic Details
Published in:International journal of antimicrobial agents 2005, Vol.25 (1), p.11-25
Main Authors: Li, Jian, Nation, Roger L., Milne, Robert W., Turnidge, John D., Coulthard, Kingsley
Format: Article
Language:English
Subjects:
Acinetobacter baumannii
Acinetobacter baumannii - drug effects
Activity
Anti-Bacterial Agents - pharmacokinetics
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Colistin
Colistin - pharmacokinetics
Colistin - pharmacology
Colistin - therapeutic use
Drug Resistance, Multiple, Bacterial
Gram-Negative Bacteria - drug effects
Gram-Negative Bacterial Infections - microbiology
Humans
Klebsiella pneumoniae
Klebsiella pneumoniae - drug effects
Medical sciences
Microbial Sensitivity Tests
Pharmacodynamics
Pharmacokinetics
Pharmacology. Drug treatments
Pseudomonas aeruginosa
Pseudomonas aeruginosa - drug effects
Resistance
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Infections caused by multi-resistant Gram-negative bacteria, particularly Pseudomonas aeruginosa, are increasing worldwide. In patients with cystic fibrosis (CF), resistance in P. aeruginosa to numerous anti-pseudomonal agents is becoming common. The absence since 1995, of new substances active against resistant Gram-negative bacteria, has caused increasing concern. Colistin, an old antibiotic also known as polymyxin E, has attracted more interest recently because of its significant activity against multi-resistant P. aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae, and the low resistance rates to it. Because its use as an anti-pseudomonal agent was displaced by the potentially less toxic aminoglycosides in 1970s, our knowledge of this drug is limited. However, there has been a significant recent increase in the data gathered on colistin, focussing on its chemistry, antibacterial activity, mechanism of action and resistance, pharmacokinetics, pharmacodynamics and new clinical application. It is likely that colistin will be an important antimicrobial option against multi-resistant Gram-negative bacteria, for some years to come.
ISSN:0924-8579
1872-7913
DOI:10.1016/j.ijantimicag.2004.10.001